multiple-myeloma
(6)
Legend Biotech
Legend Biotech turned an experiment from a room the size of a freight elevator into a medicine used to treat more than 10,000 people. Now it must prove that one demanding, personalized therapy can become a platform for the next generation of cancer care.
Arcellx
Arcellx rebuilt a crucial part of CAR-T therapy with a compact synthetic binder. Its lead treatment is now under FDA review - and the company behind it has become part of Gilead's Kite.
K36 Therapeutics, Inc.
K36 Therapeutics is a Cambridge, Massachusetts clinical-stage biotech developing first-in-class oral small-molecule inhibitors of NSD2/MMSET, an epigenetic enzyme that drives hard-to-treat cancers. Its lead candidate, gintemetostat (KTX-1001), is in Phase 1 for relapsed/refractory multiple myeloma carrying the t(4;14) translocation, and a second program, KTX-2001, targets metastatic castration-resistant prostate cancer. Backed by Atlas Venture, F-Prime Capital, Eight Roads Ventures, Nextech Invest and Bristol Myers Squibb, K36 has raised roughly $100M+ to translate chromatin biology into precision cancer medicines.
Terrence Connolly
Terrence (Terry) Connolly is a chemist-turned-dealmaker who runs K36 Therapeutics, a Cambridge, Massachusetts biotech chasing a single target: NSD2/MMSET, an epigenetic switch that drives hard-to-treat cancers. A Ph.D. organic chemist who started at the lab bench making molecules at Roche, Wyeth and Celgene, he crossed over into business development at Celgene, closed more than two dozen deals, then ran the business side at Skyhawk and Dragonfly. In 2021 he took the top job at K36, and now steers its lead compounds KTX-1001 (for t(4;14) multiple myeloma) and KTX-2001 (for treatment-resistant prostate cancer) through early clinical trials, backed by a $70 million Series B led by Nextech Invest with Bristol Myers Squibb participating.
Cheng Liu
Cheng Liu is the founder, President, and CEO of Eureka Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Emeryville, California. A molecular cell biologist trained at UC Berkeley and Peking University, Liu invented a novel class of TCR mimic antibodies that allow engineered T cells to recognize intracellular tumor antigens - a major challenge in treating solid tumors. Since founding Eureka in 2006 after a decade at Chiron/Novartis, he has built a pipeline of ARTEMIS T-cell therapies targeting liver cancer, multiple myeloma, and neuroblastoma, with the company's ECT204 program earning FDA RMAT Designation in January 2026 - one of the highest-priority designations the FDA gives to regenerative medicine therapies. Eureka has raised over $168 million in total funding and holds more than 500 patents worldwide.
Rami Elghandour
Rami Elghandour is Chairman and CEO of Arcellx (NASDAQ: ACLX), a clinical-stage biotechnology company developing next-generation cell therapies for cancer and autoimmune diseases. An engineer turned venture capitalist turned serial CEO, he has led two successful IPOs, built two multibillion-dollar public companies, and raised over $1.75 billion in capital. At Arcellx, he transformed the company from an early-stage startup into a commercial-ready organization with a peak valuation exceeding $6 billion, advancing the anito-cel BCMA CAR-T therapy toward FDA approval for relapsed/refractory multiple myeloma. A TEDx speaker on unconscious bias and gender equity, Rami is also an executive producer of the Oscar-nominated documentary 'The Voice of Hind Rajab' and the Sundance-premiered 'American Doctor.'